Comment on CMS-2026-1256-0002

Summary: AdvaMed, an organization representing medical technology companies, submitted a mixed-stance comment on the FY 2027 IPPS Proposed Rule. They support several proposals, including certain MS-DRG consolidations and the TEAM model's quality reporting, but oppose the repeal of alternative NTAP and TPT pathways for Breakthrough Devices and request the retention of specific revision MS-DRGs.